Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Treasury Shares (2021 - 2025)

Cytek Biosciences (CTKB) has disclosed Treasury Shares for 5 consecutive years, with $13.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed N/A year-over-year to $13.9 million, compared with a TTM value of $13.9 million through Dec 2025, changed N/A, and an annual FY2025 reading of $13.9 million, changed N/A over the prior year.
  • Treasury Shares was $13.9 million for Q4 2025 at Cytek Biosciences, up from $3.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $13.9 million in Q4 2025 and bottomed at $104876.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $2.9 million, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Treasury Shares soared 1015.13% in 2022, then tumbled 89.88% in 2023.
  • Year by year, Treasury Shares stood at $104876.0 in 2021, then skyrocketed by 1015.13% to $1.2 million in 2022, then skyrocketed by 465.52% to $6.6 million in 2023, then plummeted by 66.82% to $2.2 million in 2024, then skyrocketed by 532.44% to $13.9 million in 2025.
  • Business Quant data shows Treasury Shares for CTKB at $13.9 million in Q4 2025, $3.3 million in Q3 2025, and $3.3 million in Q2 2025.